semaglutide nih reduces diabetes risk and weight in schizophrenia patients semaglutide [TUSOM | Pharmwiki]

That gap is one of the more useful things in the post, since it shows the headline number does not transfer across populations

Phentermine-topiramate (Qsymia) and naltrexone-bupropion (Contrave) remain prescribed options, offering alternatives for patients who may not respond well to newer GLP-1 receptor agonists

It can affect people of all ages, but it is more commonly seen in individuals who are overweight, have insulin resistance, or have certain hormonal disorders

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): A phase 3, double-blind, randomised, multicentre, placebo-controlled trial

That decision depends on diagnosis and insurer

It can also interfere with your weight loss goals, hydration levels, and blood sugar stability